These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32735689)

  • 1. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
    Coelho AR; Oliveira PJ
    Eur J Clin Invest; 2020 Oct; 50(10):e13366. PubMed ID: 32735689
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
    Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase.
    Xu Y; Jiang H
    Protein Cell; 2020 Oct; 11(10):699-702. PubMed ID: 32761523
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
    Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
    Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
    Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
    Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
    Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
    J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
    Möhn N; Saker F; Bonda V; Respondek G; Bachmann M; Stoll M; Wattjes MP; Stangel M; Skripuletz T
    J Neurol; 2020 Oct; 267(10):2803-2805. PubMed ID: 32494855
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    Maghzi AH; Houtchens MK; Preziosa P; Ionete C; Beretich BD; Stankiewicz JM; Tauhid S; Cabot A; Berriosmorales I; Schwartz THW; Sloane JA; Freedman MS; Filippi M; Weiner HL; Bakshi R
    J Neurol; 2020 Oct; 267(10):2790-2796. PubMed ID: 32494856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
    Jones SW; Penman SL; French NS; Park BK; Chadwick AE
    Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
    Severa M; Farina C; Salvetti M; Coccia EM
    Front Immunol; 2020; 11():1459. PubMed ID: 32655578
    [No Abstract]   [Full Text] [Related]  

  • 11. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.
    Tiscornia JE; Poggio TV; Feinsilber DG; Coleman AE
    Skinmed; 2020; 18(4):254-255. PubMed ID: 33050993
    [No Abstract]   [Full Text] [Related]  

  • 13. [SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
    Ladoux A; Azoulay S; Dani C
    Med Sci (Paris); 2020; 36(6-7):555-558. PubMed ID: 32558640
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatments for COVID-19: where are we now?
    Mendes A
    Br J Community Nurs; 2020 Aug; 25(8):412-413. PubMed ID: 32757900
    [No Abstract]   [Full Text] [Related]  

  • 15. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 16. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
    Dal Moro F; Livi U
    Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
    [No Abstract]   [Full Text] [Related]  

  • 17. Curing COVID-19.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2020 Oct; 20(10):1101. PubMed ID: 32919520
    [No Abstract]   [Full Text] [Related]  

  • 18. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxytocin as a potential defence against Covid-19?
    Soumier A; Sirigu A
    Med Hypotheses; 2020 Jul; 140():109785. PubMed ID: 32344303
    [No Abstract]   [Full Text] [Related]  

  • 20. Teriflunomide and its mechanism of action in multiple sclerosis.
    Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H
    Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.